Compare Incyte Corporation (INCY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Incyte Corporation trades at $117.61 (market cap $23.11B), while iShares 0 3 Month Treasury Bond ETF trades at $100.59. The key difference: Incyte Corporation is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SGOV | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Fixed Income |
52-Week High | $118.52 | $100.74 |
52-Week Low | $67.38 | $100.28 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59, up slightly by 0.01% today. Technical indicators show a bullish trend with strong moving average support, though oscillators are neutral. The ETF provides exposure to short-term U.S. Treasury bills, offering liquidity and a low expense ratio of 0.09%. Recent news highlights institutional interest, such as Advisortrust Partners LLC acquiring a $615,000 position.
The outlook for SGOV is stable, benefiting from its role as a cash management tool amid rate uncertainty. Investment appeal lies in its safety and yield relative to cash, but risks include potential Fed rate hikes impacting short-term bond prices. Investors seeking low-risk income may find SGOV attractive, though returns are modest compared to equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
